SPAG6 silencing inhibits the growth of the malignant myeloid cell lines SKM-1 and K562 via activating p53 and caspase activation-dependent apoptosis

Yang,Bihui; Wang,Li; Luo,Xiaohua; Chen,Liping; Yang,Zesong; Liu,Lin

doi:10.3892/ijo.2014.2768

SPAG6 silencing inhibits the growth of the malignant myeloid cell lines SKM-1 and K562 via activating p53 and caspase activation-dependent apoptosis

Authors:
- Bihui Yang
- Li Wang
- Xiaohua Luo
- Liping Chen
- Zesong Yang
- Lin Liu
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, P.R. China
Published online on: November 18, 2014 https://doi.org/10.3892/ijo.2014.2768
Pages: 649-656

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

SPAG6, which is a novel cancer-testis antigen, is overexpressed in myeloid malignancies. Previously, SPAG6 was found in UPD (uniparental disomy) region of myeloid cell DNA from MDS patients and reported that SPAG6 may be a predictive marker of minimal residual disease in pediatric acute myeloid, but the biological role of SPAG6 in myeloid malignancies remains unclear. The present study was undertaken to determine the expression and functional significance of SPAG6 in malignant myeloid hematologic cell lines. A short hairpin RNA (shRNA) targeting SPAG6 was designed that could specifically inhibit SPAG6 expression at the mRNA and protein levels when introduced into the malignant myeloid hematologic cell lines SKM-1 and K562. The results from flow cytometry and CCK-8 assays showed that SPAG6 silencing inhibited the proliferation of SKM-1/K562 by inducing apoptosis. Furthermore, SPAG6 silencing resulted in activation of caspase-3, -9 and -8 and upregulated the mRNA and protein expression of p53 and PTEN. Then, we subcutaneously inoculated the monoclonal cells into NOD/SCID mice to establish xenograft models, and we found that the SPAG6-shRNA lentivirus dramatically inhibited tumor growth and increased apoptosis in vivo. These findings demonstrate that SPAG6 might have a role in malignant myeloid hematologic cell proliferation and apoptosis by regulating caspase proteins and p53, suggesting that SPAG6 may be a potential therapeutic target.

View Figures

View References

1	Cogle CR, Craig BM, Rollison DE and List AF: Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 117:7121–7125. 2011. View Article : Google Scholar : PubMed/NCBI
2	Ferrara F and Schiffer CA: Acute myeloid leukaemia in adults. Lancet. 381:484–495. 2013. View Article : Google Scholar : PubMed/NCBI
3	Schanz J, Tuchler H, Sole F, et al: New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge. J Clin Oncol. 30:820–829. 2012. View Article : Google Scholar : PubMed/NCBI
4	Steensma DP and List AF: Genetic testing in the myelodysplastic syndromes: molecular insights into hematologic diversity. Mayo Clinic Proceedings. 80:681–698. 2005. View Article : Google Scholar : PubMed/NCBI
5	Pellagatti A, Cazzola M, Giagounidis AA, et al: Gene expression profiles of CD34⁺ cells in myelodysplastic syndromes: involvement of interferon-stimulated genes and correlation to FAB subtype and karyotype. Blood. 108:337–345. 2006. View Article : Google Scholar : PubMed/NCBI
6	Zhang Z, Jones BH, Tang W, et al: Dissecting the axoneme interactome: the mammalian orthologue of Chlamydomonas PF6 interacts with sperm-associated antigen 6, the mammalian orthologue of Chlamydomonas PF16. Mol Cell Proteomics. 4:914–923. 2005. View Article : Google Scholar : PubMed/NCBI
7	Zhang Z, Sapiro R, Kapfhamer D, et al: A sperm-associated WD repeat protein orthologous to Chlamydomonas PF20 associates with Spag6, the mammalian orthologue of Chlamydomonas PF16. Mol Cell Biol. 22:7993–8004. 2002. View Article : Google Scholar : PubMed/NCBI
8	Silina K, Zayakin P, Kalnina Z, et al: Sperm-associated antigens as targets for cancer immunotherapy: expression pattern and humoral immune response in cancer patients. J Immunother. 34:28–44. 2011. View Article : Google Scholar
9	Steinbach D, Schramm A, Eggert A, et al: Identification of a set of seven genes for the monitoring of minimal residual disease in pediatric acute myeloid leukemia. Clin Cancer Res. 12:2434–2441. 2006. View Article : Google Scholar : PubMed/NCBI
10	Mulaw MA, Krause A, Deshpande AJ, et al: CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12. Leukemia. 26:1012–1019. 2012. View Article : Google Scholar
11	Nakagawa T, Matozaki S, Murayama T, et al: Establishment of a leukaemic cell line from a patient with acquisition of chromosomal abnormalities during disease progression in myelodysplastic syndrome. Br J Haematol. 85:469–476. 1993. View Article : Google Scholar : PubMed/NCBI
12	Andersson LC, Nilsson K and Gahmberg CG: K562 - a human erythroleukemic cell line. Int J Cancer. 23:143–147. 1979. View Article : Google Scholar : PubMed/NCBI
13	Scherr M and Eder M: Gene transfer into hematopoietic stem cells using lentiviral vectors. Curr Gene Ther. 2:45–55. 2002. View Article : Google Scholar : PubMed/NCBI
14	Wang L, Luo J, Nian Q, Xiao Q, Yang Z and Liu L: Ribosomal protein S14 silencing inhibits growth of acute myeloid leukemia transformed from myelodysplastic syndromes via activating p53. Hematology. 19:225–231. 2014. View Article : Google Scholar
15	Nian Q, Xiao Q, Wang L, et al: SPARC silencing inhibits the growth of acute myeloid leukemia transformed from myelodysplastic syndrome via induction of cell cycle arrest and apoptosis. Int J Mol Med. 33:856–862. 2014.PubMed/NCBI
16	Storti P, Donofrio G, Colla S, et al: HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. Leukemia. 25:527–537. 2011. View Article : Google Scholar
17	Yoon H, Lee DJ, Kim MH and Bok J: Identification of genes concordantly expressed with Atoh1 during inner ear development. Anat Cell Biol. 44:69–78. 2011. View Article : Google Scholar : PubMed/NCBI
18	Kiselak EA, Shen X, Song J, et al: Transcriptional regulation of an axonemal central apparatus gene, sperm-associated antigen 6, by a SRY-related high mobility group transcription factor, S-SOX5. J Biol Chem. 285:30496–30505. 2010. View Article : Google Scholar : PubMed/NCBI
19	van der Bruggen P, Traversari C, Chomez P, et al: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 254:1643–1647. 1991. View Article : Google Scholar : PubMed/NCBI
20	Germano S, Kennedy S, Rani S, et al: MAGE-D4B is a novel marker of poor prognosis and potential therapeutic target involved in breast cancer tumorigenesis. Int J Cancer. 130:1991–2002. 2012. View Article : Google Scholar
21	Wang L, Fidler C, Nadig N, et al: Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. Haematologica. 93:994–1000. 2008. View Article : Google Scholar : PubMed/NCBI
22	Barretina J, Caponigro G, Stransky N, et al: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483:603–607. 2012. View Article : Google Scholar : PubMed/NCBI
23	Fulda S and Debatin KM: Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene. 25:4798–4811. 2006. View Article : Google Scholar : PubMed/NCBI
24	Hengartner MO: The biochemistry of apoptosis. Nature. 407:770–776. 2000. View Article : Google Scholar : PubMed/NCBI
25	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
26	Reed JC and Pellecchia M: Apoptosis-based therapies for hematologic malignancies. Blood. 106:408–418. 2005. View Article : Google Scholar : PubMed/NCBI
27	Kranz D and Boutros M: A synthetic lethal screen identifies FAT1 as an antagonist of caspase-8 in extrinsic apoptosis. EMBO J. 33:181–197. 2014.PubMed/NCBI
28	Kittler R, Pelletier L, Heninger A-K, et al: Genome-scale RNAi profiling of cell division in human tissue culture cells. Nat Cell Biol. 9:1401–1412. 2007. View Article : Google Scholar : PubMed/NCBI
29	Polager S and Ginsberg D: p53 and E2f: partners in life and death. Nat Rev Cancer. 9:738–748. 2009. View Article : Google Scholar : PubMed/NCBI
30	Chappell WH, Steelman LS, Long JM, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget. 2:1352011.PubMed/NCBI
31	Ashkenazi A, Holland P and Eckhardt SG: Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J Clin Oncol. 26:3621–3630. 2008. View Article : Google Scholar : PubMed/NCBI
32	Gonzalvez F and Ashkenazi A: New insights into apoptosis signaling by Apo2L/TRAIL. Oncogene. 29:4752–4765. 2010. View Article : Google Scholar : PubMed/NCBI